{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T18:36:17Z","timestamp":1763318177656,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Danish Regions Medicine Grants","award":["16\/2885"],"award-info":[{"award-number":["16\/2885"]}]},{"DOI":"10.13039\/100008368","name":"Gigtforeningen","doi-asserted-by":"publisher","award":["R188-A6592"],"award-info":[{"award-number":["R188-A6592"]}],"id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manufacturer Vilhelm Pedersen and Wife\u2019s Grant after recommendation from The Novo Nordisk Foundation","award":["0060515"],"award-info":[{"award-number":["0060515"]}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","award":["19-10-0285"],"award-info":[{"award-number":["19-10-0285"]}],"id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Health Science Research Fund of the North Denmark Region","award":["2016-017615"],"award-info":[{"award-number":["2016-017615"]}]},{"name":"The Department of Rheumatology at Aalborg University Hospital"},{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006304","name":"Aalborg University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate tumour necrosis factor inhibitor (TNFi) drug-levels and presence of anti-drug antibodies (ADAb) in patients with inflammatory arthritis who taper TNFi compared to TNFi continuation. Patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis on stable TNFi dose and in low disease activity\u2009\u2265\u200912\u00a0months were randomised (2:1) to disease activity-guided tapering or control. Blood samples at baseline, 12- and 18-months were evaluated for TNFi drug-levels and ADAb. In total, 129 patients were randomised to tapering (n\u2009=\u200988) or control (n\u2009=\u200941). Between baseline and month 18, a significant shift in TNFi drug-levels were observed in the tapering group resulting in fewer patients with high drug-levels (change: \u2212\u00a014% [95% CI \u2212\u00a027 to \u2212\u00a01%]) and more with low drug-levels (change: 18% [95% CI 5\u201331%]). Disease activity was equivalent between groups at 18\u00a0months, mean difference: RA \u2212\u00a00.06 (95% CI \u2212\u00a00.44 to 0.33), PsA 0.03 (95% CI \u2212\u00a00.36 to 0.42), and axSpA 0.16 (\u2212\u00a00.17 to 0.49), equivalence margins\u2009\u00b1\u20090.5 disease activity points. ADAb were detected in eight patients, all from the tapering group. TNFi drug-level category or ADAb were not predictive for achieving successful tapering at 18\u00a0months. TNFi drug-levels decreased during tapering which indicate adherence to the tapering algorithm. Despite the difference in TNFi drug-levels at 18\u00a0months, disease activity remained equivalent, and only few tapering patients had detectable ADAb. These data do not support using TNFi drug-level and\/or ADAb to guide the tapering decision but future research with larger trials is needed.<\/jats:p><jats:p>Trial registration: EudraCT: 2017-001970-41, December 21, 2017.<\/jats:p>","DOI":"10.1007\/s00296-024-05665-7","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:01:50Z","timestamp":1721786510000},"page":"1897-1908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-7175","authenticated-orcid":false,"given":"Line","family":"Uhrenholt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads E. R.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-8288","authenticated-orcid":false,"given":"Karen B.","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5984-5134","authenticated-orcid":false,"given":"Kirsten","family":"Duch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-2922","authenticated-orcid":false,"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6600-0631","authenticated-orcid":false,"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-9174","authenticated-orcid":false,"given":"Ellen-Margrethe","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-841X","authenticated-orcid":false,"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads N. B.","family":"Rasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0792-0366","authenticated-orcid":false,"given":"Hans Christian","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-9643","authenticated-orcid":false,"given":"Kaspar R.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-5234","authenticated-orcid":false,"given":"Salome","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"5665_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","volume":"77","author":"S Henaux","year":"2018","unstructured":"Henaux S, Ruyssen-Witrand A, Cantagrel A, Barnetche T, Fautrel B, Filippi N, Lukas C, Raffeiner B, Rossini M, Degbo\u00e9 Y, Constantin A (2018) Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 77:515\u2013522. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212423","journal-title":"Ann Rheum Dis"},{"key":"5665_CR2","doi-asserted-by":"publisher","first-page":"CD010455","DOI":"10.1002\/14651858.CD010455","volume":"5","author":"LM Verhoef","year":"2019","unstructured":"Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N, den Broeder AA (2019) Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 5:CD010455. https:\/\/doi.org\/10.1002\/14651858.CD010455","journal-title":"Cochrane Database Syst Rev"},{"key":"5665_CR3","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1093\/rheumatology\/keab902","volume":"61","author":"L Uhrenholt","year":"2022","unstructured":"Uhrenholt L, Christensen R, Dinesen WKH, Liboriussen CH, Andersen SS, Dreyer L, Schlemmer A, Hauge EM, Skrubbeltrang C, Taylor PC, Kristensen S (2022) Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 61:3107\u20133122. https:\/\/doi.org\/10.1093\/rheumatology\/keab902","journal-title":"Rheumatology (Oxford)"},{"key":"5665_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","volume":"52","author":"J Ruwaard","year":"2023","unstructured":"Ruwaard J, L\u2019 Ami MJ, Kneepkens EL, Krieckaert C, Nurmohamed MT, Hooijberg F, van Kuijk A, van Denderen JC, Burgemeister L, Rispens T, Boers M, Wolbink GJ (2023) Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. Scand J Rheumatol 52:129\u2013136. https:\/\/doi.org\/10.1080\/03009742.2022.2028364","journal-title":"Scand J Rheumatol"},{"key":"5665_CR5","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","volume":"78","author":"W Ye","year":"2018","unstructured":"Ye W, Tucker LJ, Coates LC (2018) Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs 78:1705\u20131715. https:\/\/doi.org\/10.1007\/s40265-018-0994-3","journal-title":"Drugs"},{"key":"5665_CR6","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/rheumatology\/keab741","volume":"61","author":"CAJ Michielsens","year":"2022","unstructured":"Michielsens CAJ, den Broeder N, Mulder MLM, van den Hoogen FHJ, Verhoef LM, den Broeder AA (2022) Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. Rheumatology (Oxford) 61:2307\u20132315. https:\/\/doi.org\/10.1093\/rheumatology\/keab741","journal-title":"Rheumatology (Oxford)"},{"key":"5665_CR7","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Comp\u00e1n","year":"2016","unstructured":"Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, de Miguel E, Balsa A, Mart\u00edn-Mola E, Seoane-Mato D, Ca\u00f1ete JD (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford) 55:1188\u20131194. https:\/\/doi.org\/10.1093\/rheumatology\/kew033","journal-title":"Rheumatology (Oxford)"},{"key":"5665_CR8","doi-asserted-by":"publisher","first-page":"1759720X2092944","DOI":"10.1177\/1759720X20929441","volume":"12","author":"T Zhang","year":"2020","unstructured":"Zhang T, Zhu J, He D, Chen X, Wang H, Zhang Y, Xue Q, Liu W, Xiang G, Li Y, Yu Z, Wu H (2020) Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study. Ther Adv Musculoskelet Dis 12:1759720X20929441. https:\/\/doi.org\/10.1177\/1759720X20929441","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5665_CR9","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","volume":"81","author":"CA Michielsens","year":"2022","unstructured":"Michielsens CA, den Broeder N, van den Hoogen FH, Mahler EA, Teerenstra S, van der Heijde D, Verhoef LM, den Broeder AA (2022) Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Ann Rheum Dis 81:1392\u20131399. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222260","journal-title":"Ann Rheum Dis"},{"key":"5665_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/03009742.2023.2164979","volume":"52","author":"L Uhrenholt","year":"2023","unstructured":"Uhrenholt L, Christensen R, Dreyer L, Hauge EM, Schlemmer A, Loft AG, Rasch M, Horn HC, Gade KH, \u00d8stg\u00e5rd RD, Taylor PC, Duch K, Kristensen S (2023) Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial. Scand J Rheumatol 52:481\u2013492. https:\/\/doi.org\/10.1080\/03009742.2023.2164979","journal-title":"Scand J Rheumatol"},{"key":"5665_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203893","volume":"74","author":"DY Chen","year":"2015","unstructured":"Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, Hung WT, Lan JL (2015) Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 74:e16. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203893","journal-title":"Ann Rheum Dis"},{"key":"5665_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-019-2009-5","volume":"21","author":"JE Gehin","year":"2019","unstructured":"Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E (2019) Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. Arthritis Res Ther 21:256. https:\/\/doi.org\/10.1186\/s13075-019-2009-5","journal-title":"Arthritis Res Ther"},{"key":"5665_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","volume":"83","author":"A Hoxha","year":"2016","unstructured":"Hoxha A, Calligaro A, Tonello M, Ramonda R, Carletto A, Paolazzi G, Bortolotti R, Del Ross T, Grava C, Boaretto M, Favaro M, Teghil V, Ruffatti A, Punzi L (2016) The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Jt Bone Spine 83:167\u2013171. https:\/\/doi.org\/10.1016\/j.jbspin.2015.04.020","journal-title":"Jt Bone Spine"},{"key":"5665_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/03009742.2021.1875040","volume":"50","author":"JE Gehin","year":"2021","unstructured":"Gehin JE, Warren DJ, Syversen SW, Lie E, Sexton J, Loli L, Wier\u00f8d A, Bj\u00f8ro T, Kvien TK, Bolstad N, Goll GL (2021) Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. Scand J Rheumatol 50:445\u2013454. https:\/\/doi.org\/10.1080\/03009742.2021.1875040","journal-title":"Scand J Rheumatol"},{"key":"5665_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/annrheumdis-2015-208849","volume":"76","author":"M Jani","year":"2017","unstructured":"Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, BRAGGSS (2017) High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis 76:208\u2013213. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208849","journal-title":"Ann Rheum Dis"},{"key":"5665_CR16","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/art.3916","volume":"67","author":"M Jani","year":"2015","unstructured":"Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators (2015) Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 67:2011\u20132019. https:\/\/doi.org\/10.1002\/art.3916","journal-title":"Arthritis Rheumatol"},{"key":"5665_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kev298","volume":"55","author":"DY Chen","year":"2016","unstructured":"Chen DY, Chen YM, Hsieh TY, Hung WT, Hsieh CW, Chen HH, Tang KT, Lan JL (2016) Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford) 55:143\u2013148. https:\/\/doi.org\/10.1093\/rheumatology\/kev298","journal-title":"Rheumatology (Oxford)"},{"key":"5665_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028517","volume":"9","author":"L Uhrenholt","year":"2019","unstructured":"Uhrenholt L, Schlemmer A, Hauge EM, Christensen R, Dreyer L, Suarez-Almazor ME, Kristensen S (2019) Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). BMJ Open 9:e028517. https:\/\/doi.org\/10.1136\/bmjopen-2018-028517","journal-title":"BMJ Open"},{"key":"5665_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, G\u00f8tzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869. https:\/\/doi.org\/10.1136\/bmj.c869","journal-title":"BMJ"},{"key":"5665_CR20","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, CONSORT Group (2012) Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308:2594\u20132604. https:\/\/doi.org\/10.1001\/jama.2012.87802","journal-title":"JAMA"},{"key":"5665_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594. https:\/\/doi.org\/10.1136\/bmj.g7594","journal-title":"BMJ"},{"key":"5665_CR22","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS (2015) Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162:W1-73. https:\/\/doi.org\/10.7326\/M14-0698","journal-title":"Ann Intern Med"},{"key":"5665_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/17425255.2017.1320390","volume":"13","author":"C Bouman","year":"2017","unstructured":"Bouman C, van Herwaarden N, van den Hoogen F, van der Maas A, van den Bemt B, den Broeder AA (2017) Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. Expert Opin Drug Metab Toxicol 13:597\u2013604. https:\/\/doi.org\/10.1080\/17425255.2017.1320390","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5665_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/BTT.S262511","volume":"14","author":"L Pedersen","year":"2020","unstructured":"Pedersen L, Szecsi PB, Johansen PB, Bjerrum PJ (2020) Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study. Biologics 14:115\u2013125. https:\/\/doi.org\/10.2147\/BTT.S262511","journal-title":"Biologics"},{"issue":"4","key":"5665_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","volume":"77","author":"MJ L'Ami","year":"2018","unstructured":"L\u2019Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ (2018) Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 77(4):484\u2013487. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211781","journal-title":"Ann Rheum Dis"},{"key":"5665_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L (2017) Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31:299\u2013316. https:\/\/doi.org\/10.1007\/s40259-017-0231-8","journal-title":"BioDrugs"},{"key":"5665_CR27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","volume":"79","author":"P Emery","year":"2020","unstructured":"Emery P, Burmester GR, Naredo E, Sinigaglia L, Lagunes I, Koenigsbauer F, Conaghan PG (2020) Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis 79:1023\u20131030. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217246","journal-title":"Ann Rheum Dis"},{"key":"5665_CR28","unstructured":"Marotte H, Rinaudo-Gaujous M, Paul S, Fautrel B (2016) TNF blocker concentrations or detection of antibodies against anti-TNF before a tapering process are not predictive to relapse.\u00a0Arthritis Rheumatol\u00a068:S10. https:\/\/acrabstracts.org\/abstract\/tnf-blocker-concentrations-or-detection-of-antibodies-against-anti-tnf-before-a-tapering-process-are-not-predictive-to-relapse\/. Accessed 22 June 2022"},{"key":"5665_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE (2015) Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 29:241\u2013258. https:\/\/doi.org\/10.1007\/s40259-015-0134-5","journal-title":"BioDrugs"},{"key":"5665_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/rheumatology\/key292","volume":"58","author":"FBG Lamers-Karnebeek","year":"2019","unstructured":"Lamers-Karnebeek FBG, Jacobs JWG, Radstake TRDJ, van Riel PLCM, Jansen TL (2019) Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity. Rheumatology (Oxford) 58:427\u2013431. https:\/\/doi.org\/10.1093\/rheumatology\/key292","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05665-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T02:04:41Z","timestamp":1726193081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5665"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05665-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LU has received speakers fee from AbbVie, Eli-Lilly, Janssen, and Novartis; travel expenses from Abbvie (All unrelated to this manuscript); KBL has received speakers fee from Thermo Fisher Scientific (Unrelated to this manuscript); LD has received speakers fee from Eli Lilly, Galderma, and Janssen, research grants to Aalborg University Hospital from BMS and AbbVie (All unrelated to this manuscript); EMH has received fees for speaking and\/or consulting from Novo, and Novartis; research grants to Aarhus University Hospital from Independent Research Fund Denmark, Novo Nordic Foundation, Danish Rheumatism Association, Aarhus University, Danish Regions Medicine Grants, Galapagos, and AbbVie; travel expenses from Pfizer, Sobi, and AbbVie; has been principal investigator in trials by SynACT Pharma, and involved as site principal investigator in trials by AbbVie, Novartis, Novo Nordisk, and Sanofi (All unrelated to this manuscript); AGL has received speakers fee from MSD, Novartis and Pfizer, and participated on advisory boards by Eli-Lilly, Janssen, Novartis, and UCB (All unrelated to this manuscript); MNBR has received speakers fee from Sobi Scientific (Unrelated to this manuscript); HCH has participated on an advisory board by Janssen Scientific (Unrelated to this manuscript); PCT has received consulting fees from AbbVie, Biogen, Eli-Lilly, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Sanofi, and UCB, research grants from Galapagos (All unrelated to this manuscript); MERS, KD, RC, KRN, and SK declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No external editing support was used in this work. No part of this manuscript is copied, published, or archived elsewhere in whole or in part in any languages apart from the congress abstract publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The North Denmark Region Committee on Health Research Ethics (N-20170073), the Danish Medicine Agency (2017091722), and the Danish Data Protection Agency (2017-194) gave approval for the study. BIODOPT complied with the Declaration of Helsinki and was on December 21, 2017, registered at EudraCT (2017-001970-41).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave written informed consent before enrolment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}